MedTrace Logo

A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity

NCT07395687 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 333

Last updated 2026-04-21

No results posted yet for this study

Summary

The purpose of this clinical study is to find out if UBT251 is safe and effective for treating people who are living with overweight or obesity. Participants will get either UBT251 (the treatment being tested) or Placebo (a treatment that has no active medicine in it), which treatment participants get is decided by chance.

Conditions

Interventions

DRUG

UBT251

UBT251 injection will be administered subcutaneously in a lifted fold of the abdominal skin.

DRUG

Placebo

Placebo matched to UBT251 injection will be administered subcutaneously in a lifted fold of the abdominal skin.

Sponsors & Collaborators

Principal Investigators

  • Clinical Transparency (dept. 2834) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-02
Primary Completion
2027-01-14
Completion
2027-02-18
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07395687 on ClinicalTrials.gov